Ocular Melanoma clinical trials at UCSF
1 research study open to eligible people
Ocular melanoma is a rare cancer of the eye. UCSF is studying a two-drug oral regimen given first to people with metastatic uveal melanoma. The trial has multiple arms and includes patients with HLA-A*02:01 negative status.
Showing trials for
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
open to eligible people ages 18 years and up
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
San Francisco, California and other locations
Last updated: